Trump administration won’t cover anti-obesity drugs through Medicare, AP reports

The Trump administration has declined to cover expensive, high-demand obesity treatments under the federal government’s Medicare program, Tom Murphy of The Associated Press reports. The Centers for Medicare and Medicaid Services will not cover the medications under Medicare’s Part D prescription drug coverage. Trump’s Health and Human Services secretary, Robert F. Kennedy Jr., has been an outspoken opponent of the injectable drugs, which have exploded in popularity due to the potentially life-changing weight loss that some patients experience, the report notes. The Fly notes that Novo Nordisk (NVO) manufactures Ozempic and Wegovy, while Eli Lilly (LLY) produces Zepbound.